盐酸屈他维林治疗肠易激综合征100例疗效观察

目的探讨盐酸屈他维林治疗肠易激综合征（Irritable bowel syndrome，IBS）的疗效和安全性。方法选择在我院治疗的肠易激综合征患者200例，随机分为实验组和对照组，每组各100例。实验组患者给予盐酸屈他维林80mg tid治疗，对照组患者给予安慰剂治疗。嘱受试者每天记录腹痛、腹胀、排便急迫及排便费力等症状的严重程度及其发作频率。观察实验组服药期间有无头晕、恶心等不适，并进行严重程度的评估。治疗4周后评定患者的症状以明确疗效。结果两组患者治疗前在腹痛、腹胀、里急后重、排便急迫感及排便困难等症状方面差异均无统计学意义（P〉0．05）。治疗4周后实验组患者有效率明显优于对照组（P〈0．01）。实验组开始服用盐酸屈他维林时，3例患者出现轻微头晕、恶心等症状，未给予特殊处理后症状消失。结论盐酸屈他维林治疗肠易激综合征有一定疗效且安全性高。

Clincial efficacy and security of drotaverine hydrochloride in the treatment of 100 cases of irritable bowel syndrome.

Objective To investigate the efficacy and security of drotaverine hydrochloride in the treatment of irritable bowel syndrome （IBS）. Methods Two hundred patients with IBS treated in our hospital were randomly divided into the experimental group and the control group （n=100 each）. Drotaverine hydrochloride 80 mg rid treatment was given to the patients of the experimental group, while placebo was given to the patients of the control group. The patients were asked to record abdominal pain, bloating, bowel urgency and other symptoms of straining the severity and frequency of attacks daily. And dizziness, nausea and discomfort, and conduct assessment of severity were observed during the medication in the experimental group. The patient＇s symptoms were assessed to evaluate the clincial efficacy after four weeks of treatment. Results Before treatment, the two groups showed no statistically significant difference in abdominal pain, bloating, tenesmus, defecation urgency and defecation difficulties and other symptoms （P〉0.05）. After four weeks of treatment, the effective rate of the experimental group were significantly better than that in the control group （P〈0.01）. At the beginning of taking drotaverine hydrochloride, three patients in the experimental group had mild dizziness, nausea and other symptoms, which disappeared without special care. Conclusions Drotaverin hydrochloride has a certain effect on IBS, with good security.